insights_auto
Why is ALNOV up 4.65%?
Dive Deeperchevron_right
ALNOV:EPA
Novacyt SA
€0.45
arrow_upward
+4.65%(+0.020) 1D
Nov 13, 5:35:28 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.44
High
€0.46
Low
€0.43
Mkt. cap
30.13M
Avg. vol.
164.75K
Volume
156.80K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
Open
€0.44
High
€0.46
Low
€0.43
Mkt. cap
30.13M
Avg. vol.
164.75K
Volume
156.80K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
TradingKey
·
5 hours ago
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
Foreign Policy Journal
·
4 hours ago
Dow Jones Industrial Average (DJIA) Stays Green While Nasdaq Tumbles Nearly 1% In Sharp Rotation Trade
TradingView
·
12 hours ago
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Traders Union
·
12 hours ago
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
FoundedJul 3, 2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitenovacyt.com